PEB
16/02/2016 17:31
GENERAL
NOT PRICE SENSITIVE
REL: 1731 HRS Pacific Edge Limited
GENERAL: PEB: PE Announces New Commercial Partnership in Australia
16 February 2016
Pacific Edge Announces New Commercial Partnership in Australia
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has announced a
new commercial partnership with Tolmar Australia Pty Limited, a specialised
uro-oncology company which provides medicine and support to men with advanced
prostate cancer.
Tolmar will provide sales and marketing for Pacific Edge's Cxbladder tests in
Australia, supported by the Pacific Edge team in New Zealand and the
company's Melbourne based in-country manager.
Tolmar has a team of eight highly skilled and specialised sales people across
Australia, who work closely with urologists and cancer experts to market and
sell its proprietary palliative treatment for patients with advanced prostate
cancer. The new commercial arrangement with Pacific Edge will see Tolmar's
sales people encouraging trial and commercial use of Cxbladder with
urologists.
Pacific Edge Chief Executive Officer, David Darling, commented: "Tolmar has
well developed relationships in the uro-cancer community and is highly
regarded by urologists and cancer experts. This commercial partnership
between the two companies will provide greater awareness and access to
Cxbladder for healthcare specialists and their patients in Australia.
"Our User Programmes continue to be a critical element in encouraging
urologists to trial our products in their clinical settings prior to
commercial use. We expect to see an increasing number of User Programmes in
Australia going forward as we build our presence and look to boost commercial
sales in this market."
Tolmar Australia general manager, Dieter Torheiden, said: "Cxbladder
technology provides an innovative and high performing suite of tests for the
detection and better management of bladder cancer and we see them as
providing significant value to the uro-oncology specialists that we work with
on a daily basis.
"We are looking forward to the opportunity of working with Pacific Edge to
promote Cxbladder to our customers across Australia."
Bladder cancer has the ninth highest incidence rate in the world but is
highly treatable if detected in the early stages. In Australia, an estimated
42,000 people present with haematuria each year, one of the early signs of
bladder cancer, with nearly 3,000 people in Australia estimated to have
bladder cancer in 2015 . A number of validation studies have positioned
Cxbladder as a leading non-invasive diagnostic tool for the early detection
and management of bladder cancer.
ENDS
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies. Pacific Edge has
two proprietary, novel, accurate, molecular diagnostic products in-market
providing actionable results, and better detection and management of
urothelial cancer. Cxbladder Detect is available through the company's
dedicated CLIA certified laboratories for customers in New Zealand, Australia
and the USA. Cxbladder Triage is available in New Zealand and Australia.
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated
being available in the US in 2016.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient's urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.
Refer to www.cxbladder.com for more information.
End CA:00277728 For:PEB Type:GENERAL Time:2016-02-16 17:31:38
